Hexa Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Hexa Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 7 Products, $850.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Hexa Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 7 Products, $850.1K Trade | TransData Nexus

Hexa Healthcare Private Limited

Indian Pharmaceutical Exporter · Medical Devices & Diagnostics Specialist · $850.1K Total Trade · DGFT Verified

Hexa Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $850.1K across 7 products in 5 therapeutic categories. Based on 83 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Strip ($250.0K), Semaglutide ($214.3K), Cyclosporine ($142.8K).

Hexa Healthcare Private Limited — Export Portfolio & Destination Treemap

Hexa Healthcare Private Limited pharmaceutical export portfolio — 7 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Hexa Healthcare Private Limited? — Company Overview & Market Position

Hexa Healthcare Private Limited is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2021, the company is headquartered in Bengaluru, Karnataka, India. It operates under the Corporate Identification Number (CIN) U51909KA2021PTC146617 and is registered with the Registrar of Companies (RoC) Bangalore. The company has an authorized capital of ₹1.50 million and a paid-up capital of ₹0.50 million. As of September 2025, Hexa Healthcare Private Limited employs approximately 10 individuals. The company's registered office is located at 2nd Floor (West Facing), #16, AGBG Layout, Saraswathipuram Main Road, Nandini Layout, Bengaluru, Karnataka, 560096, India.

What Does Hexa Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Strip$250.0K 2Semaglutide$214.3K

Product Portfolio — Top 7 by Export Value

Hexa Healthcare Private Limited exports 7 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Strip	Medical Devices & Diagnostics	$250.0K	5	0.1%	14
2	Semaglutide	Advanced Diabetes Medications	$214.3K	18	4.3%	7
3	Cyclosporine	Immunosuppressants	$142.8K	11	1.2%	11
4	Tiotropium	Respiratory	$118.0K	25	0.1%	7
5	Torsemide	Diuretics	$99.4K	16	0.5%	11
6	Acarbose	Advanced Diabetes Medications	$14.8K	4	0.2%	11
7	Saxagliptin	Advanced Diabetes Medications	$10.8K	4	0.3%	5

Hexa Healthcare Private Limited exports 7 pharmaceutical products across 5 therapeutic categories with a total export value of $850.1K. The top category is Medical Devices & Diagnostics (29.4% of portfolio), followed by Advanced Diabetes Medications (28.2%), indicating a concentrated portfolio with the top 5 products accounting for 97.0% of total export value.

Hexa Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Hexa Healthcare Private Limited's manufacturing facilities are situated in Bengaluru, Karnataka, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing plant locations, capacities, and specializations are not publicly disclosed.

3Key Leadership

The leadership team of Hexa Healthcare Private Limited comprises:

Garvit Agarwal: Director, appointed on April 16, 2021.

Sumitra Devi: Director, appointed on December 27, 2022.

The company's leadership is responsible for overseeing operations and strategic direction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Hexa Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Hexa Healthcare Private Limited's export activities are primarily focused on Mauritius, Singapore, and Malaysia. The company has engaged in 94,228 shipments to 20 buyers in these markets, with key exported products falling under HSN Codes 3004, 3003, and 3006. Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available.

2Emerging Markets

Hexa Healthcare Private Limited has established a presence in emerging markets, notably in Mauritius, Singapore, and Malaysia. The company's engagement in these markets is facilitated by its export activities, with a focus on finished pharmaceutical formulations. Specific information regarding WHO prequalification or other certifications enabling access to these markets is not publicly disclosed.

3Geographic Strategy

Hexa Healthcare Private Limited's export strategy is concentrated in select markets, including Mauritius, Singapore, and Malaysia. This focused approach suggests a deliberate strategy to establish a strong foothold in these regions. However, the company's limited geographic diversification may expose it to risks associated with over-reliance on specific markets. Strategic expansion into additional regions could mitigate such risks and enhance the company's global presence.

Hexa Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Hexa Healthcare Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities are primarily focused on Mauritius, Singapore, and Malaysia, and there is no publicly disclosed evidence of FDA approvals or registrations.

2WHO & EU GMP

Details regarding Hexa Healthcare Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's export activities are concentrated in Mauritius, Singapore, and Malaysia, and there is no publicly disclosed evidence of WHO or EU GMP certifications.

3CDSCO & Indian Regulatory

Specific information regarding Hexa Healthcare Private Limited's compliance with the Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) is not publicly available. The company's export activities are primarily focused on Mauritius, Singapore, and Malaysia, and there is no publicly disclosed evidence of CDSCO or state drug controller approvals.

Hexa Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Hexa Healthcare Private Limited operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not publicly disclosed, the company faces competition from other pharmaceutical exporters targeting similar markets. Market share comparisons and head-to-head analyses are not available due to the lack of publicly disclosed data.

2Key Differentiators

Hexa Healthcare Private Limited's key differentiators include its specialization in finished pharmaceutical formulations and its focused export strategy in select markets. The company's concentration on Mauritius, Singapore, and Malaysia allows it to tailor its offerings to the specific needs of these regions. However, the limited diversification may also pose challenges in mitigating market-specific risks.

3Strategic Position

Hexa Healthcare Private Limited's current strategic direction appears to be focused on exporting finished pharmaceutical formulations to select markets, including Mauritius, Singapore, and Malaysia. The company's future outlook may involve expanding its product portfolio and geographic reach to enhance its global presence and mitigate risks associated with market concentration.

Buyer Due Diligence Brief — Evaluating Hexa Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Hexa Healthcare Private Limited has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with 94,228 shipments to 20 buyers in Mauritius, Singapore, and Malaysia. The company's export volume and consistency suggest reliability in fulfilling international orders. However, the lack of publicly available information regarding certifications and regulatory approvals may require further due diligence by potential partners.

2Certifications to Verify

Importers should verify the following certifications when considering Hexa Healthcare Private Limited as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Hexa Healthcare Private Limited

How many pharmaceutical products does Hexa Healthcare Private Limited export from India?

Hexa Healthcare Private Limited exports 7 pharmaceutical products across 5 therapeutic categories. The top exports are Strip ($250.0K), Semaglutide ($214.3K), Cyclosporine ($142.8K), Tiotropium ($118.0K), Torsemide ($99.4K). Total export value is $850.1K.

What is Hexa Healthcare Private Limited's total pharmaceutical export value?

Hexa Healthcare Private Limited's total pharmaceutical export value is $850.1K, based on 83 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Hexa Healthcare Private Limited cover?

Hexa Healthcare Private Limited exports across 5 therapeutic categories. The largest are Medical Devices & Diagnostics (29.4%, 1 products), Advanced Diabetes Medications (28.2%, 3 products), Immunosuppressants (16.8%, 1 products).

Get Full Hexa Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.